Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

10. Februar 2014 aktualisiert von: Boehringer Ingelheim

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1878

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Bouge/Namur, Belgien
        • 1160.67.32008 Boehringer Ingelheim Investigational Site
      • Brasschaat, Belgien
        • 1160.67.32011 Boehringer Ingelheim Investigational Site
      • Edegem, Belgien
        • 1160.67.32005 Boehringer Ingelheim Investigational Site
      • Genk, Belgien
        • 1160.67.32002 Boehringer Ingelheim Investigational Site
      • Gilly, Belgien
        • 1160.67.32006 Boehringer Ingelheim Investigational Site
      • Hasselt, Belgien
        • 1160.67.32003 Boehringer Ingelheim Investigational Site
      • Leuven, Belgien
        • 1160.67.32001 Boehringer Ingelheim Investigational Site
      • Tienen, Belgien
        • 1160.67.32004 Boehringer Ingelheim Investigational Site
      • Bourgas, Bulgarien
        • 1160.67.59007 Boehringer Ingelheim Investigational Site
      • Dimitrovgrad, Bulgarien
        • 1160.67.59009 Boehringer Ingelheim Investigational Site
      • Pleven, Bulgarien
        • 1160.67.59003 Boehringer Ingelheim Investigational Site
      • Pleven, Bulgarien
        • 1160.67.59012 Boehringer Ingelheim Investigational Site
      • Rousse, Bulgarien
        • 1160.67.59006 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59001 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59002 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59004 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59005 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59008 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgarien
        • 1160.67.59010 Boehringer Ingelheim Investigational Site
      • Berlin, Deutschland
        • 1160.67.49001 Boehringer Ingelheim Investigational Site
      • Berlin, Deutschland
        • 1160.67.49007 Boehringer Ingelheim Investigational Site
      • Dresden, Deutschland
        • 1160.67.49017 Boehringer Ingelheim Investigational Site
      • Hannover, Deutschland
        • 1160.67.49006 Boehringer Ingelheim Investigational Site
      • Homburg/Saar, Deutschland
        • 1160.67.49019 Boehringer Ingelheim Investigational Site
      • Ludwigshafen am Rhein, Deutschland
        • 1160.67.49008 Boehringer Ingelheim Investigational Site
      • Neuss, Deutschland
        • 1160.67.49015 Boehringer Ingelheim Investigational Site
      • Rostock, Deutschland
        • 1160.67.49004 Boehringer Ingelheim Investigational Site
      • Aarhus C, Dänemark
        • 1160.67.45001 Boehringer Ingelheim Investigational Site
      • Hvidovre, Dänemark
        • 1160.67.45003 Boehringer Ingelheim Investigational Site
      • Odense, Dänemark
        • 1160.67.45002 Boehringer Ingelheim Investigational Site
      • Roskilde, Dänemark
        • 1160.67.45004 Boehringer Ingelheim Investigational Site
      • HUS, Finnland
        • 1160.67.58001 Boehringer Ingelheim Investigational Site
      • Jyväskylä, Finnland
        • 1160.67.58004 Boehringer Ingelheim Investigational Site
      • Kuopio, Finnland
        • 1160.67.58003 Boehringer Ingelheim Investigational Site
      • Pori, Finnland
        • 1160.67.58002 Boehringer Ingelheim Investigational Site
      • Brest Cedex, Frankreich
        • 1160.67.3305A Boehringer Ingelheim Investigational Site
      • Brest Cedex, Frankreich
        • 1160.67.3305B Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankreich
        • 1160.67.3303A Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankreich
        • 1160.67.3303B Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankreich
        • 1160.67.3303C Boehringer Ingelheim Investigational Site
      • Dijon Cedex, Frankreich
        • 1160.67.3303D Boehringer Ingelheim Investigational Site
      • Paris, Frankreich
        • 1160.67.3301A Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95001 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95002 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95003 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95004 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95005 Boehringer Ingelheim Investigational Site
      • Tbilisi, Georgia
        • 1160.67.95006 Boehringer Ingelheim Investigational Site
      • Amedabad, Indien
        • 1160.67.91004 Boehringer Ingelheim Investigational Site
      • Chennai, Indien
        • 1160.67.91001 Boehringer Ingelheim Investigational Site
      • Hyderabad, Indien
        • 1160.67.91005 Boehringer Ingelheim Investigational Site
      • Lucknow, Indien
        • 1160.67.91007 Boehringer Ingelheim Investigational Site
      • Mumbai, Indien
        • 1160.67.91002 Boehringer Ingelheim Investigational Site
      • Pune, Indien
        • 1160.67.91003 Boehringer Ingelheim Investigational Site
      • Pune, Indien
        • 1160.67.91006 Boehringer Ingelheim Investigational Site
      • Dublin, Irland
        • 1160.67.53001 Boehringer Ingelheim Investigational Site
      • Dublin, Irland
        • 1160.67.53002 Boehringer Ingelheim Investigational Site
      • Ascoli Piceno, Italien
        • 1160.67.39006 Boehringer Ingelheim Investigational Site
      • Milano, Italien
        • 1160.67.39003 Boehringer Ingelheim Investigational Site
      • Milano, Italien
        • 1160.67.39005 Boehringer Ingelheim Investigational Site
      • Parma, Italien
        • 1160.67.39001 Boehringer Ingelheim Investigational Site
      • S. Maria Capua Vetere (CE), Italien
        • 1160.67.39002 Boehringer Ingelheim Investigational Site
      • Torino, Italien
        • 1160.67.39004 Boehringer Ingelheim Investigational Site
      • Quebec, Kanada
        • 1160.67.11014 Boehringer Ingelheim Investigational Site
    • Alberta
      • Calgary, Alberta, Kanada
        • 1160.67.11009 Boehringer Ingelheim Investigational Site
    • British Columbia
      • Vancouver, British Columbia, Kanada
        • 1160.67.11003 Boehringer Ingelheim Investigational Site
    • Ontario
      • Cambridge, Ontario, Kanada
        • 1160.67.11012 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Kanada
        • 1160.67.11008 Boehringer Ingelheim Investigational Site
      • London, Ontario, Kanada
        • 1160.67.11018 Boehringer Ingelheim Investigational Site
      • Mississauga, Ontario, Kanada
        • 1160.67.11017 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Kanada
        • 1160.67.11010 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Kanada
        • 1160.67.11020 Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada
        • 1160.67.11004 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Kanada
        • 1160.67.11016 Boehringer Ingelheim Investigational Site
      • Terrebonne, Quebec, Kanada
        • 1160.67.11006 Boehringer Ingelheim Investigational Site
      • Busan, Korea, Republik von
        • 1160.67.82010 Boehringer Ingelheim Investigational Site
      • Daegu, Korea, Republik von
        • 1160.67.82008 Boehringer Ingelheim Investigational Site
      • Daegu, Korea, Republik von
        • 1160.67.82009 Boehringer Ingelheim Investigational Site
      • Daejeon, Korea, Republik von
        • 1160.67.82013 Boehringer Ingelheim Investigational Site
      • Daejoen, Korea, Republik von
        • 1160.67.82006 Boehringer Ingelheim Investigational Site
      • Incheon, Korea, Republik von
        • 1160.67.82007 Boehringer Ingelheim Investigational Site
      • Jeonju, Korea, Republik von
        • 1160.67.82012 Boehringer Ingelheim Investigational Site
      • Kwang-Ju, Korea, Republik von
        • 1160.67.82005 Boehringer Ingelheim Investigational Site
      • Pusan, Korea, Republik von
        • 1160.67.82011 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republik von
        • 1160.67.82001 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republik von
        • 1160.67.82002 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republik von
        • 1160.67.82003 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republik von
        • 1160.67.82004 Boehringer Ingelheim Investigational Site
      • Amsterdam, Niederlande
        • 1160.67.31001 Boehringer Ingelheim Investigational Site
      • Den Bosch, Niederlande
        • 1160.67.31003 Boehringer Ingelheim Investigational Site
      • Den Haag, Niederlande
        • 1160.67.31007 Boehringer Ingelheim Investigational Site
      • Ede, Niederlande
        • 1160.67.31009 Boehringer Ingelheim Investigational Site
      • Groningen, Niederlande
        • 1160.67.31002 Boehringer Ingelheim Investigational Site
      • Helmond, Niederlande
        • 1160.67.31006 Boehringer Ingelheim Investigational Site
      • Hoogeveen, Niederlande
        • 1160.67.31011 Boehringer Ingelheim Investigational Site
      • Rotterdam, Niederlande
        • 1160.67.31005 Boehringer Ingelheim Investigational Site
      • Spijkenisse, Niederlande
        • 1160.67.31008 Boehringer Ingelheim Investigational Site
      • Tilburg, Niederlande
        • 1160.67.31004 Boehringer Ingelheim Investigational Site
      • Drammen, Norwegen
        • 1160.67.47005 Boehringer Ingelheim Investigational Site
      • Hamar, Norwegen
        • 1160.67.47002 Boehringer Ingelheim Investigational Site
      • Haugesund, Norwegen
        • 1160.67.47003 Boehringer Ingelheim Investigational Site
      • Hønefoss, Norwegen
        • 1160.67.47004 Boehringer Ingelheim Investigational Site
      • Oslo, Norwegen
        • 1160.67.47001 Boehringer Ingelheim Investigational Site
      • Bydgoszcz, Polen
        • 1160.67.48003 Boehringer Ingelheim Investigational Site
      • Bydgoszcz, Polen
        • 1160.67.48006 Boehringer Ingelheim Investigational Site
      • Gdynia, Polen
        • 1160.67.48004 Boehringer Ingelheim Investigational Site
      • Inowroclaw, Polen
        • 1160.67.48005 Boehringer Ingelheim Investigational Site
      • Sopot, Polen
        • 1160.67.48002 Boehringer Ingelheim Investigational Site
      • Warsaw, Polen
        • 1160.67.48001 Boehringer Ingelheim Investigational Site
      • Baia Mare, Rumänien
        • 1160.67.40006 Boehringer Ingelheim Investigational Site
      • Braila, Rumänien
        • 1160.67.40005 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumänien
        • 1160.67.40001 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumänien
        • 1160.67.40003 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumänien
        • 1160.67.40004 Boehringer Ingelheim Investigational Site
      • Oradea, Rumänien
        • 1160.67.40002 Boehringer Ingelheim Investigational Site
      • Tg. Mures, Rumänien
        • 1160.67.40007 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70001 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70002 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70003 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70004 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70005 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70006 Boehringer Ingelheim Investigational Site
      • Moscow, Russische Föderation
        • 1160.67.70007 Boehringer Ingelheim Investigational Site
      • Saratov, Russische Föderation
        • 1160.67.70010 Boehringer Ingelheim Investigational Site
      • Saratov, Russische Föderation
        • 1160.67.70011 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Russische Föderation
        • 1160.67.70008 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Russische Föderation
        • 1160.67.70009 Boehringer Ingelheim Investigational Site
      • Göteborg, Schweden
        • 1160.67.46004 Boehringer Ingelheim Investigational Site
      • Göteborg, Schweden
        • 1160.67.46006 Boehringer Ingelheim Investigational Site
      • Malmö, Schweden
        • 1160.67.46007 Boehringer Ingelheim Investigational Site
      • Motala, Schweden
        • 1160.67.46005 Boehringer Ingelheim Investigational Site
      • Stockholm, Schweden
        • 1160.67.46002 Boehringer Ingelheim Investigational Site
      • Uppsala, Schweden
        • 1160.67.46001 Boehringer Ingelheim Investigational Site
      • Vaesteraas, Schweden
        • 1160.67.46003 Boehringer Ingelheim Investigational Site
      • Barcelona, Spanien
        • 1160.67.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, Spanien
        • 1160.67.34002 Boehringer Ingelheim Investigational Site
      • Madrid, Spanien
        • 1160.67.34005 Boehringer Ingelheim Investigational Site
      • Madrid, Spanien
        • 1160.67.34006 Boehringer Ingelheim Investigational Site
      • Sabadell (Barcelona), Spanien
        • 1160.67.34003 Boehringer Ingelheim Investigational Site
      • Tarragona, Spanien
        • 1160.67.34004 Boehringer Ingelheim Investigational Site
      • Hradec Kralove, Tschechische Republik
        • 1160.67.42007 Boehringer Ingelheim Investigational Site
      • Litomerice, Tschechische Republik
        • 1160.67.42005 Boehringer Ingelheim Investigational Site
      • Ostrava, Tschechische Republik
        • 1160.67.42008 Boehringer Ingelheim Investigational Site
      • Prague, Tschechische Republik
        • 1160.67.42001 Boehringer Ingelheim Investigational Site
      • Teplice, Tschechische Republik
        • 1160.67.42003 Boehringer Ingelheim Investigational Site
      • Zlin, Tschechische Republik
        • 1160.67.42002 Boehringer Ingelheim Investigational Site
      • Ivano-Frankovsk, Ukraine
        • 1160.67.38002 Boehringer Ingelheim Investigational Site
      • Kharkov, Ukraine
        • 1160.67.38004 Boehringer Ingelheim Investigational Site
      • Kharkov, Ukraine
        • 1160.67.38007 Boehringer Ingelheim Investigational Site
      • Kiev, Ukraine
        • 1160.67.38001 Boehringer Ingelheim Investigational Site
      • Kiev, Ukraine
        • 1160.67.38003 Boehringer Ingelheim Investigational Site
      • Kiev, Ukraine
        • 1160.67.38005 Boehringer Ingelheim Investigational Site
      • Nikolayev, Ukraine
        • 1160.67.38008 Boehringer Ingelheim Investigational Site
      • Odessa, Ukraine
        • 1160.67.38006 Boehringer Ingelheim Investigational Site
      • Budapest, Ungarn
        • 1160.67.36001 Boehringer Ingelheim Investigational Site
      • Budapest, Ungarn
        • 1160.67.36003 Boehringer Ingelheim Investigational Site
      • Budapest, Ungarn
        • 1160.67.36004 Boehringer Ingelheim Investigational Site
      • Debrecen, Ungarn
        • 1160.67.36002 Boehringer Ingelheim Investigational Site
      • Kecskemet, Ungarn
        • 1160.67.36007 Boehringer Ingelheim Investigational Site
      • Komarom, Ungarn
        • 1160.67.36006 Boehringer Ingelheim Investigational Site
      • Miskolc, Ungarn
        • 1160.67.36008 Boehringer Ingelheim Investigational Site
      • Mosonmagyarovar, Ungarn
        • 1160.67.36009 Boehringer Ingelheim Investigational Site
      • Zalaegerszeg, Ungarn
        • 1160.67.36005 Boehringer Ingelheim Investigational Site
    • Florida
      • Clearwater, Florida, Vereinigte Staaten
        • 1160.67.10002 Boehringer Ingelheim Investigational Site
      • Brighton, Vereinigtes Königreich
        • 1160.67.44003 Boehringer Ingelheim Investigational Site
      • Exeter, Vereinigtes Königreich
        • 1160.67.44002 Boehringer Ingelheim Investigational Site
      • Middlesbrough, Vereinigtes Königreich
        • 1160.67.44001 Boehringer Ingelheim Investigational Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications.

Exclusion criteria

  1. Long term treatment with any other oral anticoagulant
  2. Severe/disabling stroke within last 6 months
  3. Conditions associated with increased bleeding risk
  4. Anaemia or thrombocytopenia
  5. Severe renal impairment
  6. Liver disease
  7. Positive pregnancy test

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo
passendes Placebo
passendes Placebo
Experimental: Dabigatran etexilate 50mg
twice daily dosing,
capsules, twice daily, 26 weeks treatment
Experimental: Dabigatran etexilate 75mg
twice daily dosing, patients with moderate renal impairment allocated 50mg bid
capsules, twice daily, 26 weeks treatment
Experimental: Dabigatran etexilate 110mg
twice daily dosing, patients with moderate renal impairment allocated 75mg bid
capsules, twice daily, 26 weeks treatment
Experimental: dabigatran etexilate 150mg
twice daily dosing, patients with moderate renal impairment allocated 110mg bid
capsules, twice daily, 26 weeks treatment

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time
Zeitfenster: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.

A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.

All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

6 month treatment period + 2 week post treatment follow up

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment
Zeitfenster: 6 month treatment period + 2 week post treatment follow up
Number of Participants with Composite of Cardiovascular death (CVD) with non fatal myocardial infarction (MI) and non haemorrhagic stroke and All cause death (ACD), non fatal MI, severe recurrent ischaemia (SRI) and non haemorrhagic stroke during six months treatment
6 month treatment period + 2 week post treatment follow up
Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment
Zeitfenster: 6 month treatment period + 2 week post treatment follow up
Number of Participants with individual occurrence of death (cardiovascular and all-cause), non-fatal MI, severe recurrent ischaemia and non-haemorrhagic stroke during six months of treatment.
6 month treatment period + 2 week post treatment follow up
Number of Participants With Any Reduction of D-dimer Concentration
Zeitfenster: at 1 week and 4 weeks
at 1 week and 4 weeks
Change From Baseline in log10 D-dimer After 1 and 4 Weeks
Zeitfenster: Baseline and at 1 week and 4 weeks
Change from baseline in log10 D-dimer concentration after 1 and 4 weeks of dabigatran etexilate treatment compared to placebo. The standard deviation is the geometric standard deviation.
Baseline and at 1 week and 4 weeks
Number of Participants With Bleeding Events During Total Observation Time
Zeitfenster: 6 month treatment period + 2 week post treatment follow up

International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed.

A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells.

All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds (CRBE) and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).

6 month treatment period + 2 week post treatment follow up
Laboratory Analyses
Zeitfenster: 6 month treatment period + 2 week post treatment follow up
Number of patients with possible clinically significant abnormalities. Clinically significant abnormalities refers to the increase or decrease from baseline.
6 month treatment period + 2 week post treatment follow up

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. März 2008

Primärer Abschluss (Tatsächlich)

1. Oktober 2009

Studienanmeldedaten

Zuerst eingereicht

13. Februar 2008

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Februar 2008

Zuerst gepostet (Schätzen)

22. Februar 2008

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

12. März 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. Februar 2014

Zuletzt verifiziert

1. Februar 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren